UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section  
13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2024  
Johnson & Johnson (Exact name of registrant as specified in its charter)                                           
                                                                                                  
  New Jersey                         1-3215                     22-1024240                        
  (State or Other Jurisdiction of    -Commission File Number    -IRS Employer Identification No.  
  Incorporation)                                                                                  
                                                                                                  
One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (Address of Principal Executive Offices) Registrant’s 
telephone number, including area code: 732- 524-0400 Check the appropriate box below if the Form 8-Kfiling is      
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material        
pursuant to Rule 14a-12under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencementcommunications pursuant to Rule
14d-2(b)under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencementcommunications pursuant to Rule             
13e-4(c)under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   
                                                                                                    
  Title of each class               Trading Symbol(s)    Name of each exchange on which registered  
  Common Stock, Par Value $1.00     JNJ                  New York Stock Exchange                    
  5.50% Notes Due November 2024     JNJ24BP              New York Stock Exchange                    
  1.150% Notes Due November 2028    JNJ28                New York Stock Exchange                    
  1.650% Notes Due May 2035         JNJ35                New York Stock Exchange                    
                                                                                                    
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the          
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§240.12b-2of
this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant   
has elected not to use the extended transition period for complying with any new or revised financial accounting   
standards provided pursuant to Section 13(a) of the Exchange Act. ☐                                                
                                                                                                                   
  Item 8.01Other EventsOn May 20, 2024, Johnson & Johnson (the “Company”) completed the previously announced       
  public offerings of the following:(1)$1,150,000,000 aggregate principal amount of 4.800% Notes due 2029 (the     
  “2029 Notes”);(2)$1,150,000,000 aggregate principal amount of 4.900% Notes due 2031 (the “2031                   
  Notes”);(3)$850,000,000 aggregate principal amount of 4.950% Notes due 2034 (the “2034 Notes”);(4)$850,000,000   
  aggregate principal amount of 5.250% Notes due 2054 (the “2054 Notes” and, together with the 2029 Notes, the     
  2031 Notes and the 2034 Notes, the “U.S. Dollar Notes”);(5)€700,000,000 aggregate principal amount of 3.200%     
  Notes due 2032 (the “2032 Notes”);(6)€800,000,000 aggregate principal amount of 3.350% Notes due 2036 (the       
  “2036 Notes”); and(7)€1,000,000,000 aggregate principal amount of 3.550% Notes due 2044 (the “2044 Notes” and,   
  together with the 2032 Notes and the 2036 Notes, the “Euro Notes”);under the Company’s Registration Statement    
  on FormS-3,Reg.No. 333-269836.In connection with the offering of the U.S. Dollar Notes, the Company entered      
  into an underwriting agreement on May 13, 2024, which is filed as Exhibit 1.1 hereto (the “U.S. Dollar           
  Underwriting Agreement”), with J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets    
  Inc., as representatives of the several Underwriters named therein (the “U.S. Dollar Underwriters”), pursuant    
  to which the Company agreed to issue and sell the U.S. Dollar Notes to the U.S. Dollar Underwriters. The U.S.    
  Dollar Underwriting Agreement incorporates the Underwriting Agreement Standard Provisions (Debt), dated May 13,  
  2024, which is filed as Exhibit 1.2 hereto (the “Standard Provisions Agreement”).In connection with the          
  offering of the Euro Notes, the Company entered into an underwriting agreement on May 14, 2024, which is filed   
  as Exhibit 1.3 hereto (the “Euro Underwriting Agreement”), with J.P. Morgan Securities plc, Citigroup Global     
  Markets Limited, Deutsche Bank AG, London Branch and the several Underwriters named therein (the “Euro           
  Underwriters”), pursuant to which the Company agreed to issue and sell the Euro Notes to the Euro Underwriters.  
  The Euro Underwriting Agreement also incorporates the Standard Provisions Agreement.Item 9.01Financial           
  Statements and Exhibits.(d)Exhibits.Exhibit No.Description1.1Underwriting Agreement, dated May 13, 2024, among   
  Johnson & Johnson and J.P. Morgan Securities LLC, BofA Securities, Inc. and Citigroup Global Markets Inc., as    
  representatives of the several Underwriters named therein.1.2Underwriting Agreement Standard Provisions (Debt),  
  dated May 13, 2024.1.3Underwriting Agreement, dated May 14, 2024, among Johnson & Johnson and J.P. Morgan        
  Securities plc, Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and the several Underwriters   
  named therein.4.1Company Order establishing the terms of the U.S. Dollar Notes.4.2Form of 4.800% Notes due       
  2029.4.3Form of 4.900% Notes due 2031.                                                                           
                                                                                                                   
                                                                                                                   
  4.4     Form of 4.950% Notes due 2034.                                                                           
  4.5     Form of 5.250% Notes due 2054.                                                                           
  4.6     Company Order establishing the terms of the Euro Notes.                                                  
  4.7     Form of 3.200% Notes due 2032.                                                                           
  4.8     Form of 3.350% Notes due 2036.                                                                           
  4.9     Form of 3.550% Notes due 2044.                                                                           
  5.1     Opinion of Weil, Gotshal & Manges LLP.                                                                   
  5.2     Opinion of Troutman Pepper Hamilton Sanders LLP.                                                         
  23.1    Consent of Weil, Gotshal & Manges LLP (included in Exhibit 5.1 of this Current Report on Form 8-K).      
  23.2    Consent of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.2 of this Current Report on Form  
          8-K).                                                                                                    
  104     The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.                             
                                                                                                                   
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.                                     
                                                                 
                               Johnson & Johnson                 
                               (Registrant)                      
  Date: May 20, 2024    By:    /s/ Marc Larkins                  
 ─────────────────────────────────────────────────────────────── 
                               Marc Larkins Corporate Secretary  
                                                                 
